Objective. There is very limited documentation available on the effects of valproate co-
medication on the pharmacokinetics of aripiprazole in a naturalistic setting. The aim of the …

Introduction: The objective of the study was to compare the serum concentrations of the
atypical antipsychotic aripiprazole in monotherapy with the concentrations found during …

Aripiprazole, a relatively new antipsychotic drug, is metabolized by cytochrome P450 3A4
(CYP3A4) and CYP2D6 to an active metabolite, dehydroaripiprazole. As studies on …

Objective To determine the effect of aripiprazole on steady‐state pharmacokinetics of
lamotrigine in patients with bipolar I disorder who were clinically stable on lamotrigine (100 …

Aripiprazole, a novel antipsychotic drug, is metabolized by CYP3A4 and CYP2D6 forming
mainly its active metabolite dehydroaripiprazole. In this study, aripiprazole and …

Aripiprazole is a new atypical antipsychotic drug with a partial agonist activity at dopamine 2
and serotonin 1A receptors. The metabolism of aripiprazole involves both cytochrome P450 …

Aripiprazole is widely used to treat schizophrenia. Plasma levels of aripiprazole and its
active metabolite dehydroaripiprazole and their clinical responses in patients were explored …

Background The effects of paroxetine coadministration on plasma concentrations of
aripiprazole and its active metabolite, dehydroaripiprazole, were studied in 14 Japanese …

Objective: To evaluate relationships between aripiprazole dose, plasma level,
pharmacologic activity, and clinical outcome in order to evaluate the potential for therapeutic …

The objective of this study was to assess the pharmacokinetics of the antipsychotic
aripiprazole when coadministered with lithium or valproate. Two open‐label, sequential …